Back to Results
First PageMeta Content
Immune system / Epstein–Barr virus / Teplizumab / Otelixizumab / Tumor necrosis factor-alpha / Anti-CD3 monoclonal antibody / Immunosuppressive drug / Monoclonal antibody therapy / Tolerx / Monoclonal antibodies / Medicine / Immunology


Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])
Add to Reading List

Document Date: 2013-12-11 22:21:47

Open Document

File Size: 690,48 KB

Share Result on Facebook

Company

GlaxoSmithKline / Expert Reviews Ltd / Ziegler AG / Denise L Faustman Immunobiology Labs / /

Country

United States / /

/

Event

FDA Phase / /

Facility

Massachusetts General Hospital / /

MedicalCondition

reprints@expert-reviews.com EBV infection / autoimmune disorders / allergies / diabetes / EBV infection / Sjogren’s syndrome / tumor necrosis / tumor necrosis factor / acute EBV infection / diabetes mellitus / human diabetes / several autoimmune diseases / infections / EBV infections / patients’ prior EBV infection / autoimmune diseases / /

MedicalTreatment

immunosuppression / antibody therapy / /

Organization

Harvard Medical School / Massachusetts General Hospital / /

Person

Miriam Davis / Nat / /

Position

Prime Minister / competing interests disclosure The author / /

Product

DEFEND-1 / CD3 / antiCD3 / /

PublishedMedium

PLoS One / /

Technology

laser / antibodies / /

URL

www.expert-reviews.com / http /

SocialTag